lorcaserin Articles
Arena Pharma updates on lorcaserin filings in EU and USA
27 March 2012
FDA updates on obesity drug candidates
11 January 2012
Arena files complete response on lorcaserin
5 January 2012
Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response
3 August 2011
Arena and Eisai say new lorcaserin Ph III data show statistically significant weight loss
11 November 2010
In another disappointment for obesity drug candidates, US FDA declines to approve Arena/Eisai’s lorcaserin
25 October 2010
US FDA advisories say no to Arena/Eisai’s obesity drug lorcaserin; back new use for Alkermes’ Vivitrol
17 September 2010
Another entrant into obesity drug market, Arena, expects FDA panel review of lorcaserin in September
4 June 2010
Showing 1-13 of 13 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
